A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.

[1]  H. Shime,et al.  Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway , 2017, Cell Death and Differentiation.

[2]  J. Kutok,et al.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.

[3]  T. Seya,et al.  Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy , 2016, Journal of experimental & clinical cancer research : CR.

[4]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[5]  H. Sugiyama,et al.  Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy , 2016, Oncoimmunology.

[6]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[7]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[8]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[9]  T. Seya,et al.  Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia , 2016, Oncoimmunology.

[10]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[11]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[12]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[13]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[14]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[15]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[16]  H. Shime,et al.  Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo , 2015, Nature Communications.

[17]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[18]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[19]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[20]  Sun Park,et al.  Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation. , 2014, Experimental cell research.

[21]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[22]  P. Greenberg,et al.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction. , 2014, Trends in immunology.

[23]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[24]  R. Steinman,et al.  Direct Type I IFN but Not MDA5/TLR3 Activation of Dendritic Cells Is Required for Maturation and Metabolic Shift to Glycolysis after Poly IC Stimulation , 2014, PLoS biology.

[25]  Michael Y. Gerner,et al.  Cutting Edge: IL-12 and Type I IFN Differentially Program CD8 T Cells for Programmed Death 1 Re-expression Levels and Tumor Control , 2013, The Journal of Immunology.

[26]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[27]  A. Kamphorst,et al.  Manipulating the PD-1 pathway to improve immunity. , 2013, Current opinion in immunology.

[28]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[29]  Yan Zheng,et al.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.

[30]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[31]  yang-xin fu,et al.  Type I interferon response and innate immune sensing of cancer. , 2013, Trends in immunology.

[32]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[33]  Susan M. Kaech,et al.  Transcriptional control of effector and memory CD8+ T cell differentiation , 2012, Nature Reviews Immunology.

[34]  P. Sabbatini,et al.  Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients , 2012, Clinical Cancer Research.

[35]  T. Seya,et al.  Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c+/CD8α+ dendritic cells , 2012, Oncoimmunology.

[36]  Y. Iwakura,et al.  Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors , 2012, Proceedings of the National Academy of Sciences.

[37]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[38]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[39]  R. Rappuoli,et al.  New adjuvants for human vaccines. , 2010, Current opinion in immunology.

[40]  J. Curtsinger,et al.  Inflammatory cytokines as a third signal for T cell activation. , 2010, Current opinion in immunology.

[41]  P. Kloetzel,et al.  Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells , 2010, The Journal of experimental medicine.

[42]  V. Bronte,et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.

[43]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[44]  T. Seya,et al.  The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer , 2009, Cancer Immunology, Immunotherapy.

[45]  Michelle Collazo,et al.  Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.

[46]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[47]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[48]  T. Seya,et al.  TLR3: interferon induction by double-stranded RNA including poly(I:C). , 2008, Advanced drug delivery reviews.

[49]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[50]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[51]  K. Ishii,et al.  Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses , 2006, Nature.

[52]  M. Bachmann,et al.  Chemokines: more than just road signs , 2006, Nature Reviews Immunology.

[53]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[54]  A. Levine,et al.  Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. , 1985, Cancer research.

[55]  A. Levine,et al.  Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. , 1979, Cancer research.